Papers

3

Total Citations

35

H-Index

3

About

Fabrizio Bellavia is a leading urologic surgeon and researcher at the forefront of robotic surgery innovation, with a primary focus on comparative robotic platforms and functional outcomes in prostate and bladder cancer treatment. His landmark work provides the first rigorous, propensity score-matched comparisons between the novel Hugo™ RAS system and the established daVinci platform for robot-assisted radical prostatectomy (RARP). In his 2024 study, which has already garnered 21 citations, Bellavia demonstrated that the Hugo™ system achieves perioperative outcomes comparable to the daVinci, offering a viable alternative in the rapidly expanding robotic surgery landscape. He extended this analysis with a one-year follow-up study, confirming equivalent oncological and functional results between the two platforms. Beyond prostate surgery, Bellavia has made important contributions to female sexual health after radical treatment for muscle-invasive bladder cancer (MIBC), authoring a 2025 systematic review that highlights this often-overlooked aspect of quality of life. His work is instrumental in guiding surgical decision-making, fostering competition in the robotic market, and ensuring that patient-centered outcomes remain central to technological adoption.

Research Focus

Key Achievements

3
H-Index
3
Papers
35
Total Citations
12
Avg Citations/Paper
🏆 Most Cited Paper
Perioperative Outcomes of Robotic Radical Prostatectomy with Hugo™ RAS versus daVinci Surgical Platform: Propensity Score-Matched Comparative Analysis
21 citations · 2024
📈 Most Prolific Year: 2024 (2 Papers)
🤝 Key Collaborators: 23
🏛 Institutions: Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic

Top Papers

  1. 1
  2. 2
  3. 3

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago